
Episode #5
Peter Donnelly of Genomics: Genetics as Nature's Drug Trial
Ninety-five percent of drug targets fail, and Professor Sir Peter Donnelly thinks the reason is simple: we can't run experiments on humans. Genetics is the next best thing. People who carry natural variants in a gene show what happens when that gene is dialed up or down over a lifetime. Peter, CEO and co-founder of Genomics, joins Steve Labkoff and Leon Rozenblit to explain how his company harmonized tens of thousands of genetic studies into one resource, what genetics revealed about "good" cholesterol, why the AI agent sits on top rather than at the core, and what genetics still can't tell a drug developer.

